CryoLife, Inc. (NYSE:CRY) Scheduled to Post Earnings on Monday
CryoLife, Inc. (NYSE:CRY) is set to issue its quarterly earnings data after the market closes on Monday, July 24th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. CryoLife has set its FY17 guidance at $0.40-0.43 EPS.
CryoLife (NYSE:CRY) last posted its quarterly earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The business had revenue of $45.10 million for the quarter, compared to analysts’ expectations of $44.64 million. CryoLife had a net margin of 5.73% and a return on equity of 7.77%. CryoLife’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. On average, analysts expect CryoLife to post $0.43 EPS for the current fiscal year and $0.52 EPS for the next fiscal year.
Shares of CryoLife, Inc. (NYSE:CRY) opened at 19.70 on Monday. CryoLife, Inc. has a one year low of $11.81 and a one year high of $20.30. The company has a 50-day moving average of $18.79 and a 200-day moving average of $17.93. The company has a market capitalization of $655.22 million, a PE ratio of 63.96 and a beta of 0.99.
A number of brokerages have recently commented on CRY. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Thursday, June 8th. Northland Securities reissued a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research report on Friday, April 28th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $20.80.
In other news, VP Amy Horton sold 9,577 shares of CryoLife stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the transaction, the vice president now owns 112,282 shares of the company’s stock, valued at approximately $2,245,640. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.